Prostate cancer: WHO standardization of PSA tests: Clinical consequences

Nature Reviews Urology

Volumn 6, Issue 6, 2009, Pages 303-305

  Stephan, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CLINICAL LABORATORY; IMMUNOASSAY; LABORATORY TEST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; SHORT SURVEY; STANDARDIZATION; BLOOD; HUMAN; MALE; NOTE; PROSTATE TUMOR; STANDARD; WORLD HEALTH ORGANIZATION;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE STANDARDS; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 77649195776     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.94     Document Type: Short Survey

References (10)

1. Jansen, F. H., Roobol, M., Bangma, C. H. & van schaik, R. H. Clinical impact of new prostate-specific antigen wHO standardization on biopsy rates and cancer detection. Clin. Chem. 54, 1999-2006 (2008).
2. vignati, G. & Giovanelli, L. standardization of PSA measures: a reappraisal and an experience with wHO calibration of Beckman Coulter Access Hybritech total and free PsA. Int. J. Biol. Markers 22, 295-301 (2007).
3. stephan, C. et al. Toward metrological traceability in the determination of prostatespecific antigen (PsA): calibrating Beckman Coulter Hybritech Access PSA assays to wHO standards compared with the traditional Hybritech standards. Clin. Chem. Lab. Med. 46, 623-629 (2008).
4. Fillée, C., Philippe, M. & Tombal, B. impact of total PSA (TPsA) wHO calibration on decision points in screening for prostate cancer [abstract]. Eur. Urol. Suppl. 7, 141 (2008).
5. Catalona, w. J. et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J. Urol. 151, 1283-1290 (1994).
6. stamey, T. A. second stanford Conference on international standardization of Prostatespecific Antigen immunoassays: september 1 and 2, 1994. Urology 45, 173-184 (1995).
7. Rafferty, B., Rigsby, P., Rose, M., stamey, T. & Gaines Das, R. Reference reagents for prostate-specific antigen (PsA): establishment of the first international standards for free PSA and PSA (90:10). Clin. Chem. 46, 1310-1317 (2000).
8. Link, R. e. et al. variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. J. Urol. 171, 2234-2238 (2004).
9. stephan, C. et al. interchangeability of measurements of total and free prostatespecific antigen in serum with 5 frequently used assay combinations: an update. Clin. Chem. 52, 59-64 (2006).
10. slev, P. R., La-ula, s. L. & Roberts, w. L. intermethod differences in results for total PsA, free PsA, and percentage of free PsA. Am. J. Clin. Pathol. 129, 952-958 (2008).